Initial public offer of 21,022,222 equity shares of face value of Rs. 2 each ("equity shares") of Glenmark Life Sciences Limited ("Company" or "Issuer") for cash at a price of Rs. 720 per equity share (including a share premium of Rs. 718 per equity share) aggregating to Rs. 1513.60 crores (the "offer") comprising a fresh issue of 14,722,222 equity shares aggregating to Rs. 1060 crores (the "fresh issue") and an offer for sale of up to 6,300,000 equity shares by Glenmark Pharmaceuticals Limited ("Promoter Selling Shareholder") and such equity shares, The "offered shares") aggregating to Rs. 453.60 crores (The "offer for sale"). The offer shall constitute 17.16% of the post-offer paid-up equity share capital of the company.
The face value of equity shares is Rs. 2 each.
Offer Price : Rs. 720 per Equity Share of face value of Rs. 2 each.
Anchor Investor offer price: Rs. 720 per Equity share.
The Offer Price is 360 times the face value.
Issue
Money Payable On
Opens On
Closes On
Application
Allotment
27-Jul-2021
29-Jul-2021
₹ 720.00
₹ 0.00
Minimum Application for shares in Nos : 20.0
Further Multiples of : 20.0
(₹)Cr.
Lead Managers to the Issue
Project Cost
1,060.00
BOB Capital Markets Ltd
Project Financed through Current Offer
1,513.60
Post Issue Equity Share Capital
24.51
Issue Price
₹720.00
Projects
Payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company pursuant to the Business Purchase agreement